Literature DB >> 23764015

Ecological validity and neuroanatomical correlates of the NIH EXAMINER executive composite score.

Katherine L Possin1, Amanda K LaMarre1, Kristie A Wood1, Dan M Mungas2, Joel H Kramer1.   

Abstract

Executive functions refer to a constellation of higher-level cognitive abilities that enable goal-oriented behavior. The NIH EXAMINER battery was designed to assess executive functions comprehensively and efficiently. Performance can be summarized by a single score, the "Executive Composite," which combines measures of inhibition, set-shifting, fluency, and working memory. We evaluated the ecological validity of the Executive Composite in a sample of 225 mixed neurological patients and controls using the Frontal Systems Behavior Scale (FrSBe), an informant-based measure of real-world executive behavior. In addition, we investigated the neuroanatomical correlates of the Executive Composite using voxel-based morphometry in a sample of 37 participants diagnosed with dementia, mild cognitive impairment, or as neurologically healthy. The Executive Composite accounted for 28% of the variance in Frontal Systems Behavior Scale scores beyond age. Even after including two widely used executive function tests (Trails B and Stroop) as covariates, the Executive Composite remained a significant predictor of real-world behavior. Anatomically, poorer scores on the Executive Composite were associated with smaller right and left dorsolateral prefrontal volumes, brain regions critical for good executive control. Taken together, these results suggest that the Executive Composite measures important aspects of executive function not captured by standard measures and reflects the integrity of frontal systems.

Entities:  

Mesh:

Year:  2013        PMID: 23764015      PMCID: PMC4059410          DOI: 10.1017/S1355617713000611

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  53 in total

Review 1.  Adult clinical neuropsychology: lessons from studies of the frontal lobes.

Authors:  Donald T Stuss; Brian Levine
Journal:  Annu Rev Psychol       Date:  2002       Impact factor: 24.137

2.  Voxel-based lesion-symptom mapping.

Authors:  Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

3.  Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias.

Authors:  Katherine L Possin; Dana Feigenbaum; Katherine P Rankin; Glenn E Smith; Adam L Boxer; Kristie Wood; Sherrie M Hanna; Bruce L Miller; Joel H Kramer
Journal:  Neurology       Date:  2013-05-08       Impact factor: 9.910

4.  Cognitive profile of patients with newly diagnosed Parkinson disease.

Authors:  Dino Muslimovic; Bart Post; Johannes D Speelman; Ben Schmand
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

5.  Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, and APA Division 40 members.

Authors:  Laura A Rabin; William B Barr; Leslie A Burton
Journal:  Arch Clin Neuropsychol       Date:  2005-01       Impact factor: 2.813

6.  Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function.

Authors:  Dawn I Velligan; Janice L Ritch; Dawen Sui; Margaret DiCocco; Cindy D Huntzinger
Journal:  Psychiatry Res       Date:  2002-12-30       Impact factor: 3.222

7.  Disconnection syndromes of basal ganglia, thalamus, and cerebrocerebellar systems.

Authors:  Jeremy D Schmahmann; Deepak N Pandya
Journal:  Cortex       Date:  2008-05-23       Impact factor: 4.027

8.  Self-reported executive dysfunction, neuropsychological impairment, and functional outcomes in multiple sclerosis.

Authors:  Michael R Basso; Isaac S Shields; Natasha Lowery; Courtney Ghormley; Dennis Combs; Peter A Arnett; Jay Johnson
Journal:  J Clin Exp Neuropsychol       Date:  2008-11       Impact factor: 2.475

9.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

10.  Anatomical substrates of the alerting, orienting and executive control components of attention: focus on the posterior parietal lobe.

Authors:  Xuntao Yin; Lu Zhao; Junhai Xu; Alan C Evans; Lingzhong Fan; Haitao Ge; Yuchun Tang; Budhachandra Khundrakpam; Jian Wang; Shuwei Liu
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more
  14 in total

1.  Sensitive measures of executive dysfunction in non-demented Parkinson's disease.

Authors:  Nicholas T Bott; Erica T Johnson; Norbert Schuff; Nicholas Galifianakis; Trishna Subas; Jessica Pollock; Peter Pressman; Joel H Kramer; Katherine L Possin
Journal:  Parkinsonism Relat Disord       Date:  2014-10-15       Impact factor: 4.891

Review 2.  Executive dysfunction.

Authors:  Gil D Rabinovici; Melanie L Stephens; Katherine L Possin
Journal:  Continuum (Minneap Minn)       Date:  2015-06

Review 3.  Frontotemporal dementia: diagnosis, deficits and management.

Authors:  Nicholas T Bott; Anneliese Radke; Melanie L Stephens; Joel H Kramer
Journal:  Neurodegener Dis Manag       Date:  2014

4.  Executive functions in premanifest Huntington's disease.

Authors:  S Christine You; Michael D Geschwind; Sharon J Sha; Alexandra Apple; Gabriella Satris; Kristie A Wood; Erica T Johnson; Jonathan Gooblar; Jeanne S Feuerstein; Steven Finkbeiner; Gail A Kang; Bruce L Miller; Christopher P Hess; Joel H Kramer; Katherine L Possin
Journal:  Mov Disord       Date:  2013-12-27       Impact factor: 10.338

5.  Altered Resting-State Connectivity within Executive Networks after Aneurysmal Subarachnoid Hemorrhage.

Authors:  Monica Maher; Nathan W Churchill; Airton Leonardo de Oliveira Manoel; Simon J Graham; R Loch Macdonald; Tom A Schweizer
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 6.  Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.

Authors:  Justin B Miller; Sarah J Banks; Gabriel C Léger; Jeffrey L Cummings
Journal:  Transl Neurodegener       Date:  2014-06-05       Impact factor: 8.014

7.  Regional functional connectivity predicts distinct cognitive impairments in Alzheimer's disease spectrum.

Authors:  Kamalini G Ranasinghe; Leighton B Hinkley; Alexander J Beagle; Danielle Mizuiri; Anne F Dowling; Susanne M Honma; Mariel M Finucane; Carole Scherling; Bruce L Miller; Srikantan S Nagarajan; Keith A Vossel
Journal:  Neuroimage Clin       Date:  2014-07-23       Impact factor: 4.881

8.  Combining Frontal Transcranial Direct Current Stimulation With Walking Rehabilitation to Enhance Mobility and Executive Function: A Pilot Clinical Trial.

Authors:  David J Clark; Sudeshna A Chatterjee; Jared W Skinner; Paige E Lysne; Chanoan Sumonthee; Samuel S Wu; Ronald A Cohen; Dorian K Rose; Adam J Woods
Journal:  Neuromodulation       Date:  2020-08-18

9.  Executive Functioning with the NIH EXAMINER and Inference Making in Struggling Readers.

Authors:  Kelly K Halverson; Jaye L Derrick; Luis D Medina; Paul T Cirino
Journal:  Dev Neuropsychol       Date:  2021-04-02       Impact factor: 2.253

10.  Interbatch Reliability of Blood-Based Cytokine and Chemokine Measurements in Community-Dwelling Older Adults: A Cross-Sectional Study.

Authors:  Cutter A Lindbergh; Breton M Asken; Kaitlin B Casaletto; Fanny M Elahi; Lauren A Goldberger; Corrina Fonseca; Michelle You; Alexandra C Apple; Adam M Staffaroni; Ryan Fitch; Will Rivera Contreras; Paul Wang; Anna Karydas; Joel H Kramer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-10-13       Impact factor: 6.591

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.